<DOC>
	<DOCNO>NCT01219205</DOCNO>
	<brief_summary>Although important clinical management classify BRVO subtypes base location occlusion ( major macular ) , study provide information [ 8,9 ] . The aim study evaluate outcome patient macular edema due Branch retinal vein occlusion treat intravitreal bevacizumab injection determine concentration cytokines aqueous humor accord site occlusion .</brief_summary>
	<brief_title>Major Macular Branched Retinal Venous Occlusion</brief_title>
	<detailed_description>Branch retinal vein occlusion second frequent major retinal vascular disease diabetic retinopathy . One main reason visual loss BRVO development macular edema . Treatment option BRVO include grid laser treatment , intravitreal injection steroid , surgical procedure , off-label treatment intravitreal anti-vascular endothelial growth factor ( VEGF ) agent . During recent year , intravitreal anti-VEGF treatment bevacizumab show efficiently reduce macular edema improve visual acuity numerous case series prospective retrospective study .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>macular edema involve center fovea minimum central macular thickness baseline ≥250 μm previous vitreoretinal surgery , intravitreal injection laser treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>macular edema secondary retinal benous occlusion</keyword>
</DOC>